MeiraGTx Holdings (MGTX) Non-Current Deffered Revenue (2017 - 2025)
MeiraGTx Holdings (MGTX) reported Non-Current Deffered Revenue of $65.1 million for Q4 2025, up 13.1% on a YoY basis from $57.6 million in Q4 2024, and up 1.42% quarter-over-quarter from $64.2 million in Q3 2025.
MeiraGTx Holdings (MGTX) Non-Current Deffered Revenue (2017 - 2025) Analysis & Trends
MeiraGTx Holdings has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $65.1 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deffered Revenue rose 13.1% year-over-year to $65.1 million; the trailing twelve-month figure through Dec 2025 stood at $65.1 million (up 13.1% YoY), and the FY2025 full-year result was $65.1 million, up 13.1% from the prior year.
- Non-Current Deffered Revenue for Q4 2025 stood at $65.1 million, up from $64.2 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $65.1 million in Q4 2025, with the low at $15.5 million in Q3 2022.
- Historically, Non-Current Deffered Revenue has averaged $42.2 million across 5 years, with a median of $41.2 million in 2021.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue tumbled 52.33% — and 2024, when it surged 153.99%.
- MeiraGTx Holdings' Non-Current Deffered Revenue stood at $43.0 million in 2021, then tumbled by 36.26% to $27.4 million in 2022, then rose by 23.99% to $34.0 million in 2023, then surged by 69.26% to $57.6 million in 2024, then advanced by 13.1% to $65.1 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $65.1 million (Q4 2025), $64.2 million (Q3 2025), and $63.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | MeiraGTx Holdings | 910.47 Mn | 844.54 Mn | 74.89 Mn | 65.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 65.12 Mn |
| Sep 30, 2025 | 64.21 Mn |
| Jun 30, 2025 | 63.04 Mn |
| Mar 31, 2025 | 59.62 Mn |
| Dec 31, 2024 | 57.58 Mn |
| Sep 30, 2024 | 58.90 Mn |
| Jun 30, 2024 | 53.76 Mn |
| Mar 31, 2024 | 53.33 Mn |
| Dec 31, 2023 | 34.02 Mn |
| Sep 30, 2023 | 23.19 Mn |
| Jun 30, 2023 | 25.36 Mn |
| Mar 31, 2023 | 26.43 Mn |
| Dec 31, 2022 | 27.44 Mn |
| Sep 30, 2022 | 15.49 Mn |
| Jun 30, 2022 | 21.34 Mn |
| Mar 31, 2022 | 37.28 Mn |
| Dec 31, 2021 | 43.05 Mn |
| Sep 30, 2021 | 32.49 Mn |
| Jun 30, 2021 | 39.33 Mn |
| Mar 31, 2021 | 43.30 Mn |